The value of the global mRNA combined vaccines and therapies market was estimated at **** billion U.S. dollars in 2022. Of this amount, the market for various types of cancer was the largest single market by disease group, worth over ** billion U.S. dollars. More information on the global mRNA vaccines and therapies market can be found here.

Explore Market Research Intellect's MRNA Treatment Market Report, valued at USD 5.6 billion in 2024, with a projected market growth to USD 19.2 billion by 2033, and a CAGR of 15.1% from 2026 to 2033.

• The global industry was valued at US$ 21.7 Bn in 2023
• It is projected to grow at a CAGR of -4.3% from 2023 to 2034 and reach more than US$ 9.6 Bn by the end of 2034

Market Introduction

Regional Outlook of mRNA Vaccine Industry

Global mRNA Vaccine Market Snapshot

mRNA Therapy Market Outlook

In 2023, the global market size for mRNA therapy is estimated at $5.2 billion, with a projected compound annual growth rate (CAGR) of 25.7% from 2024 to 2032. By 2032, the market is expected to reach approximately $38.3 billion, driven by factors such as advancements in biotechnology, increased investment in research and development, and growing acceptance of mRNA-based treatments. The market's rapid expansion is attributed to its potential to address various unmet medical needs, particularly in the fields of oncology, infectious diseases, and cardiovascular conditions, as well as a broadening scope of therapeutic applications.

The growth factors propelling the mRNA therapy market are multifaceted. First, the success of mRNA vaccines, particularly during the COVID-19 pandemic, has significantly boosted confidence in the efficacy and safety of mRNA technology. This breakthrough has accelerated the acceptance of mRNA as a viable therapeutic platform, paving the way for expanded applications beyond vaccines. Additionally, advancements in delivery technologies are improving the stability and efficiency of mRNA therapies, making them more feasible for clinical use. Moreover, substantial investments by both public and private sectors in mRNA research are further accelerating the development pipelines, thereby enhancing market growth.

Another critical growth factor is the increasing prevalence of chronic and infectious diseases globally. Conditions such as cancer, cardiovascular diseases, and infectious diseases remain leading causes of mortality and morbidity worldwide. mRNA therapies offer a promising approach to treating these conditions by providing a versatile platform for developing targeted and personalized treatments. For instance, mRNA can be used to instruct cells to produce proteins that fight diseases, offering a novel therapeutic mechanism. Furthermore, the ability to rapidly develop and modify mRNA sequences in response to emerging pathogens is particularly advantageous in managing infectious disease outbreaks, thus driving market expansion.

The regulatory environment is also playing a crucial role in the growth of the mRNA therapy market. Regulatory agencies worldwide are increasingly recognizing the potential of mRNA therapies and are working to streamline approval processes. This supportive regulatory landscape facilitates quicker transition from research to clinical application, thereby reducing the time to market. Additionally, collaborations between regulatory bodies and pharmaceutical companies are fostering innovation and expediting the development of new mRNA-based treatments. Such regulatory support is vital in maintaining the momentum of market growth and ensuring that new therapies reach patients promptly.

Regionally, North America dominates the mRNA therapy market, driven by robust research infrastructure, significant investments in biotechnology, and early adoption of innovative therapies. Europe follows, benefiting from strong regulatory support and substantial public funding for mRNA research. The Asia Pacific region is emerging as a lucrative market due to increasing healthcare expenditure, growing awareness about advanced therapies, and rising prevalence of chronic diseases. Latin America and the Middle East & Africa, although currently smaller markets, are witnessing gradual growth driven by improving healthcare infrastructure and increasing investment in biotechnology sectors.

Product Type Analysis

The mRNA therapy market is segmented into various product types, each catering to specific therapeutic needs. Cancer mRNA Therapy represents a significant portion of this market, driven by the urgent need for effective cancer treatments. mRNA therapies in oncology aim to stimulate the immune system to recognize and attack cancer cells, offering a targeted and potentially less toxic alternative to traditional treatments like chemotherapy. The precision and adaptability of mRNA technology make it particularly suited for developing personalized cancer vaccines, which are tailored to the unique genetic profile of an individual’s tumor, thereby enhancing treatment efficacy.

Infectious Disease mRNA Therapy is another critical segment, significantly bolstered by the successful deployment of mRNA vaccines against COVID-19. This segment’s growth is poised to continue as researchers explore mRNA-based solutions for a broad spectrum of infectious diseases, including influenza, HIV, and Zika virus. The speed at which mRNA vaccines can be developed and produced provides a strategic advantage in responding to emergin

Global mRNA Treatment market size 2025 was XX Million. mRNA Treatment Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

The global mRNA vaccines and therapeutics market size reached USD 59.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 73.4 Billion by 2033, exhibiting a growth rate (CAGR) of 2.4% during 2025-2033. The development and acceptance of mRNA-based vaccines on a global scale, the growing need for quick and adaptable solutions for emerging and re-emerging infectious diseases, and the increasing incidence of cancer and genetic diseases are some of the major factors propelling the market.

IMARC Group provides an analysis of the key trends in each segment of the global mRNA vaccines and therapeutics market report, along with forecasts at the global, regional and country levels from 2025-2033. Our report has categorized the market based on vaccine type, treatment type, vaccine manufacturing, application, and end-user.

The global market size of mRNA Vaccines & Therapeutics is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global mRNA Vaccines & Therapeutics Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global mRNA Vaccines & Therapeutics industry. The key insights of the report:
1.The report provides key statistics on the market status of the mRNA Vaccines & Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of mRNA Vaccines & Therapeutics industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of mRNA Vaccines & Therapeutics Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of mRNA Vaccines & Therapeutics as well as some small players. At least 13 companies are included:
* Argos Therapeutics
* AstraZeneca
* Bayer
* BioNTech
* Boehringer Ingelheim
* CRISPR Therapeutics
For complete companies list, please ask for sample pages.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For product type segment, this report listed main product type of mRNA Vaccines & Therapeutics market
* Standardization Of Cancer Treatment MRNA Vaccine
* Individualized Cancer Treatment MRNA Vaccine
* Infectious Disease Treatment MRNA Vaccine
* Infection Prevention MRNA Vaccine
For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Infectious Disease
* Cancer
* Other

For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

As per Cognitive Market Research's latest published report, the Global mRNA vaccine market size was $1.45 Billion in 2022 and it is forecasted to reach $3.86 Billion by 2030. mRNA vaccine Industry's Compound Annual Growth Rate will be 12.8 % from 2023 to 2030. Whereas a Self-amplifying mRNA Vaccines Market Share was 61.25%, a leading type of mRNA Vaccine. What is Driving mRNA vaccine Industry Growth?

Rise in the prevalence of infectious diseases:

Recently, emerging and re-emerging infectious diseases are posing a public health threat across the globe. This era has witnessed a wave of severe infectious disease outbreaks which has had a devastating impact on lives and livelihoods around the globe. It has been studied that increasing resistances, international traveling, the risk of bio-war attacks, and infectious diseases concern the whole world.

The infectious agents not only disrupt cell growth and proliferation but also weaken the immune system which considerably decreases the body’s ability to fight cancer-causing infections. Some viruses, bacteria and parasites also cause chronic inflammation, leading to cancers.

Further, environmental changes, caused by the intensive development of industry, as a result of globalization, which in turn affects human health. It has stimulated high prevalence of infectious diseases. For instance, a high prevalence of influenza results in mild to severe illness and even death. In industrialized countries, most deaths associated with influenza occur among people aged 65 or older.

In such cases, mRNA vaccines are widely used as both RNA and delivery vehicles exhibit intrinsic immunogenicity. By triggering pattern recognition receptors within cells, synthetic RNA leads to the production of type one interferon (IFN). Thus, the rise in the prevalence of infectious diseases drives the market of mRNA vaccines market.

Mounting R&D Investment:

Health is a prime focused parameter for regulatory bodies across the world. With the increasing prevalence of communicable and non-communicable diseases, the rate of mortality has been increased dramatically. Hence the authorities are focusing on improving the healthcare system.

With the increasing healthcare requirements and associated priorities for research and development, governments and companies are investing more monetary funds into the research and development activities. For instance, the United States has invested $194.2 billion in medical and health research and development which was grew by 6.4% from 2017 to 2018.

Fuelled by the successful utilisation of the mRNA Covid-19 vaccines, RNA therapeutics is expected to make larger strides in 2023. Hence, companies are harnessing RNA research through collaborations. Researchers say this has impacted not just companies with clinical stage-products, but also individual academic labs, which will now likely result in more RNA-focused projects in the next few years.

For instance, Sanofi has launched a dedicated vaccines mRNA Center of Excellence and has invested approximately €400 million to accelerate end-to-end R&D of next-generation vaccines, fully financed through resource reallocation. Introduction of mRNA Vaccine

mRNA is a biological substance that is given in a series of shots to protect the body from developing a disease. It works by triggering the immune system to create antibodies. These antibodies then fight bacteria and viruses that cause disease. Most mRNA vaccines are multi-antigen vaccines, where mRNA has advantages over peptide-based vaccines. For more than 30 years, healthcare providers are using this technology to prevent infectious and oncological diseases. They are also studying mRNA vaccines to treat diseases like multiple sclerosis.

Moreover, mRNA vaccines are used to prevent severe illness from COVID-19 infection. Thus, 2020 was a breakout year for mRNA therapeutics with the launch and widespread use of mRNA vaccines for COVID-19.

The value of the European mRNA combined vaccines and therapies market is forecast to reach around **** billion U.S. dollars by the end of 2030. In 2020, the market was estimated at approximately *** billion U.S. dollars. This would represent a compound annual growth rate of just over eight percent between 2020 and 2030. More information on the global mRNA vaccines and therapies market can be found here.

The mRNA therapeutics market is poised to witness substantial growth, with a market size of USD 12.17 billion in 2025 and projected to reach USD 61.14 billion by 2033, exhibiting a CAGR of 17.05% during the forecast period. The growth can be attributed to factors such as the increasing prevalence of infectious diseases, the rising incidence of chronic diseases, and the growing demand for personalized medicine. Additionally, the advancements in mRNA technology and the successful development of mRNA vaccines for COVID-19 have further accelerated the market growth. The mRNA therapeutics market is segmented based on application, type, end-use, and region. The infectious diseases segment is currently the largest application, owing to the high prevalence of infectious diseases worldwide and the potential of mRNA vaccines to provide effective protection. The prophylactic segment is expected to grow at a significant pace due to the increasing focus on preventive healthcare and the development of mRNA vaccines for a wider range of infectious diseases. The hospital and clinics segment is the major end-use segment, primarily due to the growing demand for mRNA-based therapies in treating various diseases in hospital settings. North America dominates the market, primarily due to the early adoption of mRNA technology, the presence of leading pharmaceutical companies, and the high prevalence of chronic diseases. The Asia Pacific region is expected to exhibit significant growth due to the increasing healthcare expenditure, the rising incidence of infectious diseases, and the growing awareness of mRNA-based therapies. The global mRNA therapeutics market is poised for exponential growth in the coming years. This cutting-edge technology holds immense promise for revolutionizing the treatment of various diseases. With an estimated market valuation of USD 20.5 billion in 2023, it is projected to reach a staggering USD 120 billion by 2030, exhibiting a remarkable CAGR of 24.1%. Recent developments include: In September 2023, Moderna, Inc. expanded its messenger ribonucleic acid research across oncology, respiratory, and rare diseases. This initiative was anticipated to fuel the company’s revenue , In August 2023, CureVac announced the commencement of dosing for the initial participant in a Phase 2 study. This study focuses on modified COVID-19 mRNA vaccine candidates developed through a collaboration with GSK Plc , In January 2023, BioNTech SE entered a strategic collaboration with the UK government to supply personalized messenger RNA cancer immunotherapies for up to 10,000 patients by 2030. This initiative positively impacted the company’s revenue , In January 2023, BioNTech SE completed the acquisition of InstaDeep Ltd. This initiative was anticipated to strengthen BioNTech’s AI-powdered drug discovery, design, and development .

The mRNA vaccine and therapeutics market size is estimated to be worth USD 9 billion in 2024 and is projected to be USD 1.99 billion by 2035, representing a CAGR of -23% during the forecast period from 2024 to 2035

The mRNA therapeutics market is experiencing explosive growth, driven by the significant success of COVID-19 vaccines and the expanding pipeline of therapies targeting various diseases. The market, estimated at $10 billion in 2025, is projected to achieve a robust Compound Annual Growth Rate (CAGR) of 25% from 2025 to 2033, reaching an estimated market value of $70 billion by 2033. This rapid expansion is fueled by several key factors. Firstly, the demonstrated efficacy and speed of development of mRNA vaccines against infectious diseases have established the technology's potential. Secondly, ongoing research and development are exploring mRNA therapies for a wide range of conditions, including cancer, cardiovascular diseases, and genetic disorders. The ability to precisely target specific cells and elicit tailored immune responses makes mRNA therapeutics a highly promising modality. However, challenges remain, including the need for efficient delivery systems to overcome obstacles like mRNA degradation and immunogenicity, as well as the complexities and high costs associated with manufacturing and clinical trials. Despite these challenges, the market's future looks bright. Leading pharmaceutical companies like Moderna, BioNTech/Pfizer, and CureVac are heavily invested in mRNA technology, fueling innovation and competition. Furthermore, smaller biotech companies such as Ethris, Kernal Biologics, RaNA Therapeutics, and Silence Therapeutics are contributing to the expanding pipeline of potential mRNA treatments. Geographical expansion is also anticipated, with North America and Europe currently dominating the market, but emerging markets in Asia and other regions presenting substantial growth opportunities as healthcare infrastructure improves and awareness increases. Regulatory approvals and reimbursement policies will continue to influence market growth. Continued research focusing on enhanced stability, delivery methods, and safety profiles will further unlock the full potential of mRNA therapeutics across a vast spectrum of diseases.

The global mRNA therapy market is projected to be valued at $5.3 billion in 2024, driven by factors such as increasing consumer awareness and the rising prevalence of industry-specific trends. The market is expected to grow at a CAGR of 10.1%, reaching approximately $14.1 billion by 2034.

The mRNA therapy market is experiencing robust growth, projected to reach $37.58 billion in 2025 and exhibiting a Compound Annual Growth Rate (CAGR) of 12.6% from 2025 to 2033. This significant expansion is driven by several key factors. The successful development and deployment of mRNA vaccines against COVID-19 have dramatically accelerated research and investment in this field, showcasing the technology's potential for rapid response to emerging infectious diseases. Furthermore, the versatility of mRNA technology extends beyond vaccines; it holds immense promise for treating a wide range of cancers and genetic disorders. Ongoing clinical trials are exploring the therapeutic potential of mRNA in oncology, where personalized therapies tailored to individual patient genetics offer hope for improved outcomes. The market is characterized by intense competition among major pharmaceutical companies like Moderna, BioNTech, Pfizer, and others, all vying to establish leadership in this rapidly evolving landscape. This competition fuels innovation and drives down costs, ultimately benefiting patients. While challenges remain, including potential side effects and the need for specialized cold-chain storage and delivery systems, the substantial financial backing and ongoing technological advancements suggest a bright future for mRNA therapy. The market's growth trajectory anticipates substantial expansion in the coming years, fueled by continuous research and development, growing public and private investment, and the increasing approval of new mRNA-based therapeutics. The diverse applications under investigation, ranging from infectious disease prevention to personalized cancer treatments, solidify mRNA's position as a transformative technology in healthcare. Expansion into novel therapeutic areas, improved delivery mechanisms, and the development of more efficient manufacturing processes are key elements that will shape the future landscape of the mRNA therapy market. The increasing adoption of mRNA therapies will further be influenced by expanding regulatory approvals and supportive reimbursement policies globally. Strategic partnerships and collaborations between pharmaceutical companies and research institutions are accelerating the pace of innovation and paving the way for a more impactful future for mRNA therapeutics.

[217+ Pages Report] The global Messenger RNA (mRNA) Vaccines & Therapeutics market size is expected to grow from USD 0.71 billion in 2021 to USD 26.35 billion by 2030, at a CAGR of 14.65% from 2022-2030

The mRNA Vaccines Therapeutics Market is experiencing robust growth, projected to reach a substantial size driven by several key factors. The market's Compound Annual Growth Rate (CAGR) of 16.80% from 2019-2033 signifies a significant expansion, fueled by increasing prevalence of infectious diseases, a rising incidence of cancer and autoimmune disorders, and ongoing advancements in mRNA vaccine technology. The development of self-amplifying mRNA-based vaccines, offering enhanced efficacy and reduced dosage requirements, is a major driver. Furthermore, the success of mRNA vaccines in combating the COVID-19 pandemic has accelerated research and investment in this field, leading to a wider exploration of mRNA therapeutics for various diseases. The market segmentation reveals significant opportunities across various vaccine types, applications (including cancer, infectious diseases, and autoimmune diseases), treatment types (monoclonal antibodies, gene therapy, and cell therapy), and end-users (research labs, hospitals, and clinics). The geographic distribution shows strong growth across North America and Europe, reflecting established healthcare infrastructure and high research activity. However, the Asia-Pacific region is poised for substantial expansion due to increasing healthcare spending and a growing population. The competitive landscape is dynamic, with major pharmaceutical companies like Pfizer, Moderna, BioNTech, and others actively engaged in research, development, and commercialization of mRNA vaccines and therapies. Strategic collaborations, mergers, and acquisitions are anticipated to further shape the market. While challenges such as high research and development costs, stringent regulatory approvals, and potential adverse effects might restrain market growth to some extent, the overall outlook remains positive. Continuous innovation and increasing government funding dedicated to research and development of mRNA-based therapeutics are anticipated to further accelerate market expansion. The long-term forecast suggests continued growth, driven by the expanding therapeutic applications of mRNA technology and the growing understanding of its potential to revolutionize healthcare. Recent developments include: November 2022: Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals aged 18 years and older. Health Canada previously authorized similar bivalent booster doses containing Omicron BA.1 or BA.4/5 variants from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) in September and October of 2022, respectively., October 2022: Moderna Inc. reported that it had received emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children and adolescents aged 6 to 17 years.. Key drivers for this market are: Soaring Demand for New Vaccines and Therapeutics, Rising Chronic and Infectious Diseases; Increasing R&D Investments by the Government and Market Players. Potential restraints include: Soaring Demand for New Vaccines and Therapeutics, Rising Chronic and Infectious Diseases; Increasing R&D Investments by the Government and Market Players. Notable trends are: Infectious Disease Segment is Expected to Occupy a Significant Share in the mRNA Vaccines and Therapeutics Market over the Forecast Period.

The mRNA therapy market is experiencing explosive growth, driven by the remarkable success of COVID-19 vaccines and the expanding potential applications in oncology and other therapeutic areas. The market, estimated at $15 billion in 2025, is projected to witness a robust Compound Annual Growth Rate (CAGR) of 20% between 2025 and 2033, reaching an estimated $70 billion by 2033. Key drivers include the inherent advantages of mRNA technology, such as its rapid development capabilities, high versatility in targeting various diseases, and its potential for personalized medicine. The successful application in cancer immunotherapy, particularly utilizing genetically modified T cells and transforming nanoparticles, is significantly boosting market expansion. Furthermore, advancements in mRNA delivery systems, including lipid nanoparticles and targeted delivery mechanisms, are enhancing the efficacy and safety of mRNA therapies, thereby fueling market growth. The segments demonstrating the strongest growth are mRNA targeted delivery in vivo and cancer immunotherapy, reflecting significant investment and clinical advancements in these areas. Significant market restraints include the challenges associated with mRNA stability, immunogenicity, and efficient delivery to target tissues. Regulatory hurdles and the high cost of manufacturing mRNA-based therapies also pose challenges. However, ongoing research and development efforts focused on improving mRNA stability and delivery methods, alongside streamlined regulatory processes, are expected to mitigate these constraints. Major players like Moderna, BioNTech, Pfizer, and others are actively investing in research and development, expanding production capacity, and forming strategic alliances to capitalize on the market's immense potential. Geographical expansion, particularly in emerging markets with increasing healthcare infrastructure and investment, will further propel market growth. The regional breakdown reveals strong market presence in North America and Europe, while Asia-Pacific is anticipated to showcase substantial growth in the coming years due to increasing investments in healthcare and burgeoning pharmaceutical sectors.

Snapshot img

RNA Based Therapeutics Market Size 2024-2028

The RNA based therapeutics market size is forecast to increase by USD 1.27 billion at a CAGR of 5.54% between 2023 and 2028. The market is experiencing significant growth due to several key drivers. First, the increasing number of clinical studies focusing on messenger ribonucleic acid (mRNA) technology for cancer treatment is fueling market expansion. Additionally, the immunologic characteristics of RNA-based therapeutics, such as their ability to elicit both T-cell and B-cell responses, make them an attractive option for vaccine development against infectious diseases and genetic disorders. Furthermore, pharmacologic frontiers in RNA-based therapeutics are expanding, offering new opportunities for treating rare conditions. However, the high cost of developing RNA-based therapeutics remains a significant challenge for market growth. Despite this, the potential benefits of these innovative treatments continue to draw investment and collaboration from industry players.

What will be the Size of the Market During the Forecast Period?

Request Free Sample

RNA-based therapeutics represent a groundbreaking advancement in the healthcare industry, offering innovative solutions for various medical conditions. These therapeutics leverage the intricacies of RNA, a vital biological molecule, to manipulate gene expression, protein production, and immune responses. This market encompasses a wide range of applications, including oncology, infectious diseases, neurodegenerative disorders, and chronic illnesses. The increasing prevalence of chronic illnesses and the growing demand for personalized medicine are primary drivers propelling the RNA-based therapeutics market forward. The ability of RNA-based therapies to target specific genes and proteins, as well as their potential for treating rare conditions, makes them an attractive alternative to conventional treatments.

The regulatory requirements for RNA-based therapeutics are stringent, ensuring their safety and efficacy. These therapies undergo rigorous testing and clinical trials to secure approval from regulatory bodies. The regulatory landscape is continually evolving, with ongoing efforts to streamline the approval process and facilitate the development and commercialization of these innovative treatments. RNA-based therapeutics have a wide range of applications in healthcare, including cancer clinical studies, vaccine development, and gene delivery. In oncology, RNA interference and gene delivery techniques are being explored for their potential to target specific cancer-causing genes. In infectious diseases, RNA-based therapeutics can be used to silence viral genes or enhance immune responses.

Furthermore, for neurodegenerative disorders, RNA-based therapies hold promise in modifying protein expression and addressing the underlying causes of these conditions. Innovations in RNA-Based Therapeutics: Research and academic laboratories, hospitals, and diagnostic laboratories are at the forefront of innovation in RNA-based therapeutics. Small interfering RNAs (siRNAs) and microRNAs are among the most widely studied RNA-based therapeutics, with potential applications in various medical fields. Additionally, advancements in drug delivery systems and molecular diagnostics are enabling the development of more effective and targeted RNA-based therapies. RNA-based therapeutics represent a transformative force in the healthcare industry, offering innovative solutions for a diverse range of medical conditions.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Type

  mRNA therapeutics
  Antisense oligonucleotide (ASO) therapeutics
  RNA interference (RNAi) therapeutics
  Others


Route Of Administration

  Intravenous (IV)
  Subcutaneous (SC)
  Intramuscular (IM)


Geography

  Europe

    Germany
    UK


  North America

    US


  Asia

    China
    Japan


  Rest of World (ROW)

By Type Insights

The mRNA therapeutics segment is estimated to witness significant growth during the forecast period. MRNA therapeutics represent a groundbreaking method for treating various medical conditions by instructing cells to generate specific proteins. Notable applications include cancer immunotherapies, which encode tumor-related antigens via mRNA, stimulating the immune system to attack and eliminate cancer cells. Moderna Inc. (Moderna) is pioneering mRNA-based therapies for cancer, focusing on personalized cancer drugs/vaccines and additional oncology treatments. Moreover, mRNA therapeutics are being explored for diseases like heart conditions and rare genetic disorders. In gene replacement therapies, mRNA is introduced to generate proteins that are

Snapshot img

mRNA Synthesis Raw Material Market Size 2024-2028

The mrna synthesis raw material market size is forecast to increase by USD 776.45 million at a CAGR of 4.93% between 2023 and 2028.

The market is experiencing significant growth due to the increasing prevalence of chronic and infectious diseases, which necessitates the development of advanced therapeutics. Collaborations in biotechnology and manufacturing processes related to mRNA synthesis are also driving market expansion. However, the complexity of mRNA synthesis and purification processes poses a challenge to market growth. The intricacy of these processes requires specialized expertise and advanced technology, which can increase production costs. Despite these challenges, the potential benefits of mRNA-based therapies, such as their ability to deliver precise genetic material to target cells, make them an attractive option for treating various diseases. Overall, the market for mRNA synthesis raw materials is expected to grow steadily In the coming years, as researchers and pharmaceutical companies continue to invest in this promising technology.

What will be the Size of the mRNA Synthesis Raw Material Market During the Forecast Period?

Request Free SampleThe market is experiencing significant growth due to the increasing demand for MRNA technology in various sectors, including mRNA research, mRNA-based vaccines, and therapeutic applications. With the recent success of mRNA vaccines such as those used for COVID-19, government agencies and research institutions have accelerated their investments in this technology. The flexible and durable nature of mRNA makes it an attractive alternative to traditional treatments for chronic diseases, particularly in healthcare professional-administered settings. High-quality raw materials are essential for ensuring the immunogenicity and efficacy of mRNA vaccines and therapeutics. The market is driven by advancements in RNA technology, including enzymatic capping and DNA-to-RNA transcription, which enhance the stability and efficiency of mRNA production.Applications of mRNA technology extend beyond vaccines to include therapeutics for cancer, cardiovascular diseases, tuberculosis, and other infectious diseases.

How is this mRNA Synthesis Raw Material Industry segmented and which is the largest segment?

The mrna synthesis raw material industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ApplicationVaccine productionTherapeutics productionOthersEnd-userBiopharmaceutical and pharmaceutical companiesCROs and CMOsAcademic and research institutionsGeographyNorth AmericaUSEuropeGermanyUKAsiaChinaJapanRest of World (ROW)

By Application Insights

The vaccine production segment is estimated to witness significant growth during the forecast period.

MRNA synthesis raw materials have become essential components In the production of mRNA-based vaccines and therapeutics, revolutionizing the biopharmaceutical industry. MRNA technology enables rapid development and scalability of vaccines against various infectious diseases, including HIV, tuberculosis, and cancer. Key players, such as Thermo Fisher Scientific Inc., provide high-quality mRNA synthesis reagents and kits to vaccine manufacturers. These materials are indispensable for producing mRNA-1273 and other mRNA vaccines, enabling the synthesis of proteins for patient populations. Capping agents, nucleotide segments, and enzymatic capping are crucial aspects of mRNA synthesis, ensuring improved medical technology through flexible, durable, and immunogenic vaccines and medications.Biopharmaceutical and pharmaceutical companies, CROs & CMOs, and research institutions rely on these raw materials for vaccine production and gene-editing therapies. The therapeutics segment, focusing on chronic diseases, benefits from mRNA technology, with healthcare professionals seeking high-quality raw materials for drug discovery and biotechnology companies developing nutraceuticals and diagnostics research. The nucleotide market segment, including nucleotide analogs, plays a significant role in mRNA synthesis, while capping enzymes and DNA templates are vital for therapeutics production. The use of mRNA synthesis raw materials advances medical technology, enabling the production of mRNA vaccines, medications, and gene therapies.

Get a glance at the mRNA Synthesis Raw Material Industry report of share of various segments Request Free Sample

The Vaccine production segment was valued at USD 1622.94 million in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 34% to the growth of the global market during the forecast period.

Technavio’s analysts hav

Overview

New York, NY – May 14, 2025 – Global mRNA Therapeutics Market size is expected to be worth around US$ 40.3 Billion by 2033 from US$ 18.5 Billion in 2023, growing at a CAGR of 8.1% during the forecast period 2024 to 2033.

Messenger RNA (mRNA) therapeutics represent a transformative advancement in modern medicine, enabling the body to produce specific proteins that can prevent or treat diseases. Unlike traditional therapies, mRNA-based treatments do not rely on administering synthetic proteins or altering the patient’s DNA. Instead, they deliver genetic instructions to cells, prompting them to synthesize therapeutic proteins directly.

mRNA technology gained global prominence during the COVID-19 pandemic through the rapid development of vaccines. This success has accelerated interest and investment in mRNA platforms for various therapeutic applications beyond infectious diseases. These include cancer immunotherapy, rare genetic disorders, cardiovascular diseases, and autoimmune conditions.

One of the key advantages of mRNA therapeutics is their ability to be rapidly designed, synthesized, and manufactured. This flexibility allows for quick adaptation to emerging health threats or personalized medical needs. Additionally, mRNA therapies are considered safer because they do not integrate into the patient’s genome and are eventually degraded by normal cellular processes.

Several clinical trials are currently underway evaluating mRNA drugs for melanoma, cystic fibrosis, Zika virus, and other indications. Key players in the mRNA field are collaborating with regulatory agencies to ensure safety, efficacy, and timely approvals. The growing pipeline, technological advancements in delivery systems, and supportive regulatory environment are expected to significantly boost the global mRNA therapeutics market in the coming years.